Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-04-23 Proxy Solicitation & In…
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of Annual General and Special Meeting of Shareholders, containing meeting date, agenda items (financial statements, director elections, stock option approvals, auditor appointment), and proxy voting instructions. It is a solicitation to vote and information statement for shareholders rather than the meeting materials themselves. Therefore it falls under Proxy Solicitation & Information Statement.
2025-04-23 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Schedule 14A ‘Proxy Statement’ filed under Section 14(a) of the Securities Exchange Act, titled “Notice and Proxy Statement for the Annual and Special Meeting of Shareholders.” It includes proposals to elect directors, appoint auditors, vote on executive compensation and equity plan amendments, reverse stock split resolutions, voting instructions and meeting logistics. This clearly matches a proxy solicitation information statement rather than an annual report or earnings release.
2025-04-23 English
Other.pdf
Regulatory Filings Classification · 1% confidence The document is a U.S. SEC Form 8-K “Current Report” announcing a change in the company’s independent registered public accounting firm (Item 4.01). There is no dedicated category for auditor changes in our taxonomy. It is a regulatory filing made to satisfy SEC disclosure requirements and does not match other more specific categories (e.g., Annual Report, Earnings Release, Board changes, etc.). Therefore it falls into the fallback category “Regulatory Filings” (RNS).
2025-04-22 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Schedule 14A Proxy Statement for the Annual and Special Meeting of Shareholders, including Notice of Meeting, proposals for shareholder votes, instructions to shareholders, and solicitation of proxies. It is not the full annual report or a regulatory announcement but rather the proxy solicitation materials sent to shareholders to request votes. This matches the definition of a Proxy Solicitation & Information Statement (Code: PSI).
2025-04-18 English
Material change report - English.pdf
Delisting Announcement Classification · 1% confidence The document is a Form 51-102F3 Material Change Report specifically announcing that Aptose Biosciences’ common shares will be delisted from The Nasdaq Stock Market effective April 2, 2025. It constitutes an official notice of removal of the company’s stock from an exchange, which matches the Delisting Announcement category.
2025-04-08 English
Notice of the meeting and record date (amended) - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a short notice to securities authorities regarding the details of an upcoming Annual and Special Meeting of security holders (record dates, meeting date, location, proxy materials). It is not a full annual report or earnings release, nor a post‐vote declaration. Instead, it falls under proxy solicitation materials advising on the meeting and how to access proxy voting. Therefore, it matches the Proxy Solicitation & Information Statement category (PSI).
2025-04-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.